Clinical effects of white skinned sweet potato for drug-free individuals with impaired fasting glucose and mild type 2 diabetes mellitus
2001
Kajimoto, O. (Osaka Univ. of Foreign Studies, Minoo (Japan). Center for Health Care) | Takahashi, T. | Itokawa, T.
An eight-week long-term administration trial was performed to evaluate the clinical effectiveness and safety of white skinned sweet potato (WSSP) for 26 individuals with impaired fasting glucose and mild type 2 diabetes mellitus. None of them were receiving drug therapy. WSSP was given as tablets, which were prepared after being lyophilized and powdered. The subjects were divided into two groups; one group was given the WSSP tablets, and the other was given placebo tablets. The results indicated that subjects given the WSSP tablets at 14.4g/day (0.826mg/day WSSP glycoprotein as the active ingredient) achieved significant reductions in fasting plasma glucose levels (127.0 =+- 7.1 mg/dL -> 116.8 =+- 16.3 mg/dL, Wilcoxon test: rho < 0.05). This reduction was significantly different from that in the subjects given the placebo (Mann-Whitney test: rho < 0.05). These observations support the usefulness of WSSP for the health care of individuals with impaired fasting glucose and mild type 2 diabetes mellitus.
Afficher plus [+] Moins [-]Mots clés AGROVOC
Informations bibliographiques
Cette notice bibliographique a été fournie par Agriculture, Forestry and Fisheries Research Information Technology Center
Découvrez la collection de ce fournisseur de données dans AGRIS